The global prostate-specific antigen testing market is primarily progressing growth because of the rise in prostate cancer among men, who are over 50 years in age. Furthermore, the adoption of various assay-based methods and various new inventions for the diagnosis of prostate cancer has raised the demand for PSA testing. The combination of advanced technology for PSA testing has improved the accuracy and specificity of the results playing an important role in boosting the market. Europe contributes for a huge revenue market share for prostate-specific antigen testing, accounting for nearly 45% of the global revenue. The market for prostate-specific antigen testing in 2017 was $ 2264.84 million and is expected to reach $ 2774.12 million by 2023 at an estimated CAGR of 4.14% during forecast period of 2018-2023